|
02 Aug 2021 |
Prometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Crohn’s Disease
|
|
02 Aug 2021 |
Carrick Therapeutics Announces Collaboration with Roche to Evaluate Novel Samuraciclib Combination to Treat HR+ Breast Cancer
|
|
02 Aug 2021 |
Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, "Off-the-Shelf", Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma
|
|
02 Aug 2021 |
Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy (DM1)
|
|
02 Aug 2021 |
Hummingbird Bioscience Announces UK MHRA Approval for First-in-Human Phase 1 Trial of HMBD-001 in Advanced Cancers
|
|
02 Aug 2021 |
FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate
|
|
02 Aug 2021 |
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
|
|
02 Aug 2021 |
Autolus and Moderna sign Option and License Agreement for access to proprietary targeting technology from Autolus
|
|
02 Aug 2021 |
Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic
|
|
02 Aug 2021 |
Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis
|
|
02 Aug 2021 |
Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
|
|
02 Aug 2021 |
Biophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in Sarcopenia
|
|
02 Aug 2021 |
Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
|
|
02 Aug 2021 |
Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
|
|
02 Aug 2021 |
Saphnelo (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus
|
|
31 Jul 2021 |
Revolo Biotherapeutics Announces Clinical Trial Authorization to Initiate Phase 2 Trial of ‘1104 in Allergic Disease in the UK
|
|
31 Jul 2021 |
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
|
|
31 Jul 2021 |
FDA Expands Authorized Use of REGEN-COV™ (casirivimab and imdevimab)
|
|
31 Jul 2021 |
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
|
|
31 Jul 2021 |
Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs
|
